Literature DB >> 19698745

Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia.

Carlos A Rodriguez1, Maria Agudelo, Juan C Cataño, Andres F Zuluaga, Omar Vesga.   

Abstract

We report a case of generic vancomycin treatment failure in a liver transplant patient with MRSA peritonitis and bacteremia, followed by a rapid sterilization of blood and peritoneal fluid after switching to the branded product. It raises concern about therapeutic equivalence of generic vancomycin.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19698745     DOI： 10.1016/j.jinf.2009.08.005

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


  12 in total

1.  Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model.

Authors:  Carlos A Rodriguez; Maria Agudelo; Andres F Zuluaga; Omar Vesga
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin.

Authors:  Carlos A Rodriguez; Maria Agudelo; Andres F Zuluaga; Omar Vesga
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

3.  Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.

Authors:  Omar Vesga; Maria Agudelo; Beatriz E Salazar; Carlos A Rodriguez; Andres F Zuluaga
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

4.  Nephrotoxicity comparison of two commercially available generic vancomycin products.

Authors:  Jesse D Sutton; Ryan P Mynatt; Keith S Kaye; Kyle P Murray; Michael J Rybak; Jason M Pogue
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

5.  Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model.

Authors:  Andres F Zuluaga; Maria Agudelo; John J Cardeño; Carlos A Rodriguez; Omar Vesga
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

6.  In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin.

Authors:  Carlos A Rodriguez; Maria Agudelo; Andres F Zuluaga; Omar Vesga
Journal:  BMC Infect Dis       Date:  2010-06-04       Impact factor: 3.090

7.  Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.

Authors:  M Agudelo; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

8.  Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem.

Authors:  M Agudelo; C A Rodriguez; C A Pelaez; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

9.  Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.

Authors:  Carlos A Rodriguez; Maria Agudelo; Yudy A Aguilar; Andres F Zuluaga; Omar Vesga
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

10.  Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.

Authors:  Javier M Gonzalez; Carlos A Rodriguez; Andres F Zuluaga; Maria Agudelo; Omar Vesga
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.